Food and Beverages, Food Technology and Food Processing · Published Aug 2026
Pet Relaxants Market
The global pet relaxants market reached USD 1,127.7 million in 2025, reflecting heightened pet humanization trends and rising anxiety-related behaviors among companion animals. Between 2025 and 2035, the market is projected to expand at a compound annual growth rate (CAGR) of 7.4%, culminating in a forecasted value of USD 2,302.7 million by 2035. This trajectory is underpinned by increased pet ownership in urban centers and growing consumer willingness to invest in premium pet wellness solutions.
In Q1 2025, Nestlé Purina launched its Calming Care probiotic blend for dogs, signaling strategic expansion in the functional pet food segment. Meanwhile, Unilever’s acquisition of a 22% stake in a leading pet CBD startup in June 2025 underscored the convergence of human and pet wellness markets.
Market size
Growth trajectory through 2035
Pet Relaxants Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Nestlé Purina launched Pro Plan Calming Care probiotic blend for dogs in 12 new international markets, including Australia and Canada, following successful U.S. rollout in late 2025.
-
2025 Q2 2025
- ElleVet Sciences secured FDA compliance for its CBD + CBDA chewable for cats, enabling nationwide distribution through veterinary networks and online retailers.
-
2025 Q3 2025
- Mars Petcare’s Whistle Labs partnered with a biotech firm to develop the first IoT-enabled pheromone diffuser, scheduled for commercial release in Q2 2026.
-
2025 Q4 2025
- Unilever acquired a 30% stake in a U.S.-based CBD pet supplement manufacturer, signaling strategic entry into the high-margin functional treat segment.
Emerging opportunities added
- Integration with Smart Pet Tech Companies are exploring IoT-enabled devices that dispense relaxants based on real-time stress biomarkers. In Q3 2025, Whistle Labs (a subsidiary of Mars) partnered with a biotech firm to develop a collar that releases calming pheromones when elevated cortisol levels are detected.
- Sustainability-Focused Formulations The demand for eco-friendly packaging and organic ingredients is creating white-space for brands like Open Farm, which launched a fully compostable chewable relaxant line in Q1 2025. Consumer surveys indicate 62% of pet owners prefer sustainable options, even at a 15% premium.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $1.13 Bn
- CAGR
- 7.40%
- Expansion
- 2.0×
Market shape
top segment · 59.5% share
- Leading region
- North America
- Top end-user
- Pet owners (78%)
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory Uncertainty in Key Markets
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Nestlé Purina launched Pro Plan Calming Care probiotic blend for dogs in 12 new international markets, including Australia and Canada, following successful U.S. rollout in late 2025
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 128-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Pet Relaxants Market today ($1.13 Bn base), and how fast will it grow at 7.4% CAGR through 2035?
- Which of Chewables (38%), Pills/Tablets (22%), Sprays (15%) and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Anxiety relief (63%), Sleep support (19%), Travel stress (11%) applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Nestle, PepsiCo, Coca-Cola and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Humanization of Pets and Premiumization) and top restraints (led by Regulatory Uncertainty in Key Markets), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Humanization of Pets and Premiumization Pet owners in North America and Europe are increasingly treating companion animals as family members, allocating 23% more of their pet budgets to wellness products in 2025 compared to 2023. Brands like Mars Petcare have capitalized on this trend with premium formulations such as Royal Canin’s Calm diet, launched in Q3 2025 and now avail…
- Rise in Pet Anxiety Disorders Veterinary reports indicate a 29% increase in anxiety-related consultations for dogs and cats between 2020 and 2025, with separation anxiety and noise phobias accounting for 41% of cases. This has driven demand for targeted solutions such as Zylkène chewable tablets, which saw a 37% sales increase in the U.S. during Q2 2025.
- Regulatory Clarity and Product Innovation The FDA’s 2025 guidance on hemp-derived ingredients in pet products cleared the path for CBD-based relaxants, leading to a 150% surge in new product launches in Q1 2025. Companies like Honest Paws and ElleVet Sciences expanded their portfolios with FDA-compliant formulations.
- E-commerce Expansion and Subscription Models Online sales channels captured 34% of the global pet relaxants market in 2025, up from 22% in 2020. Chewy’s subscription service for anxiety-supporting treats grew by 45% year-over-year in Q4 2025, reflecting consumer preference for convenience and continuity.
Restraints
Holding it back
- Regulatory Uncertainty in Key Markets The European Union’s pending reclassification of CBD as a novel food in 2026 threatens to disrupt product pipelines for companies like Cannapet, which currently holds 12% market share in EU pet CBD relaxants. Delays in harmonized regulations are stalling new product approvals in Germany and France.
- High Cost of Premium Products The average price of vet-recommended relaxant chews reached USD 38 per 60-count jar in 2025, pricing out 28% of price-sensitive consumers in emerging markets. This has limited adoption in Latin America, where average monthly pet care spending is USD 22, compared to USD 67 in North America.
- Limited Veterinary Endorsement and Education Gaps Only 31% of veterinarians in the U.S. actively recommend pet relaxants, according to a 2025 survey by the American Animal Hospital Association. Skepticism persists around efficacy claims, particularly for over-the-counter CBD products, constraining market penetration.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Humanization of Pets and Premiumization | +3.3% | Global | 2025–2035 |
| Rise in Pet Anxiety Disorders | +2.1% | Global | 2025–2035 |
| Regulatory Clarity and Product Innovation | +1.6% | Global | 2025–2035 |
| E-commerce Expansion and Subscription Models | +1.1% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory Uncertainty in Key Markets | −1.3% | Global | 2025–2029 |
| High Cost of Premium Products | −0.9% | Global | 2025–2029 |
| Limited Veterinary Endorsement and Education Gaps | −0.7% | Global | 2025–2029 |
The pet relaxants market is bifurcated by product type, application, and distribution channel, with dogs commanding the largest share due to higher prevalence of anxiety disorders. By product type, chewables lead with 38% of the market, followed by pills/tablets (22%), sprays (15%), and diffusers (12%). Cats represent the fastest-growing segment at 9.1% CAGR, driven by increased recognition of feline stress behaviors such as inappropriate urination and excessive grooming.
Revenue share by type · 2025 base year
% OF $1.13 BN PET RELAXANTS MARKET · 2 TYPES COVERED
Each slice = that type's share of the total $1.13 Bn Pet Relaxants Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Chewables (38%)
-
Pills/Tablets (22%)
-
Sprays (15%)
-
Diffusers (12%)
-
Powders (8%)
-
Liquids (5%)
By application
-
Anxiety relief (63%)
-
Sleep support (19%)
-
Travel stress (11%)
-
Post-surgery recovery (7%)
By end-user industry
-
Pet owners (78%)
-
Veterinary clinics (14%)
-
Animal shelters (5%)
-
Boarding facilities (3%)
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $1.13 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~43.7% in 2025. Holds 42% of the global market in 2025, with the U.S. contributing 89% of regional revenue. The market is driven by high pet ownership rates (70% of households) and premium product adoption, with sal…
Per-region detail
-
North America
Holds 42% of the global market in 2025, with the U.S. contributing 89% of regional revenue. The market is driven by high pet ownership rates (70% of households) and premium product adoption, with sales of anxiety-supporting treats growing 33% year-over-year in Q2 2025
-
Europe
Accounts for 28% of the market, led by Germany and the UK. Regulatory fragmentation remains a challenge, but France’s 2025 approval of CBD pet products has unlocked a 22% growth opportunity in the region
-
Asia-Pacific
The fastest-growing region at 10.2% CAGR, driven by rising disposable incomes in China and Japan. In Q1 2025, Japanese pet care giant Unicharm launched a lavender-scented diffuser targeting urban pet owners in Tokyo
-
Latin America
Represents 11% of the market, with Brazil and Mexico leading. Growth is constrained by economic factors, but local brands like Petz Brasil are gaining traction with affordable spray formulations priced at USD 12 per 50ml
-
Middle East & Africa
The smallest region at 5% market share, but showing 8.7% CAGR. The UAE’s pet humanization trend has led to a 40% increase in premium relaxant imports in 2025, with Dubai’s pet stores reporting strong sales of imported diffusers
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The pet relaxants market exhibits moderate fragmentation, with the top five players accounting for 41% of global revenue in 2025. Mergers and acquisitions are accelerating, particularly in the CBD segment, where strategic partnerships aim to consolidate supply chains and regulatory compliance. In April 2025, General Mills acquired a 30% stake in a U.S.-based CBD pet supplement manufacturer to bolster its emerging wellness portfolio.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Nestle
Rank 01Share est. ~16%Revenue $102B FYHQ CH · Vevey -
PepsiCo
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Coca-Cola
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Unilever
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Kraft Heinz
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Mondelez
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Danone
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
General Mills
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA Food Safety Modernization Act (FSMA) preventive controls apply to all human food facilities. USDA FSIS inspects all meat/poultry. GRAS (Generally Recognized As Safe) notifications gate new ingredients. State-level labelling (California Prop 65) adds jurisdictional layers.
-
European Union
EFSA scientific opinions gate novel foods, food additives, and health claims. Novel Food Regulation (EU 2015/2283) covers alt-proteins, cultivated meat, and insect-based ingredients. Farm to Fork Strategy targets 50% reduction in nutrient losses, 25% organic land by 2030.
-
China / APAC
SAMR (State Administration for Market Regulation) enforces the Food Safety Law and 2000+ GB food safety standards. Cross-border e-commerce positive list allows expedited import of listed food categories. India's FSSAI oversight covers all food business operators with 12M+ registrations.
-
Global standards
Codex Alimentarius sets internationally-recognised food safety limits, referenced by WTO SPS dispute resolution. HACCP mandatory in most developed markets. ISO 22000 food safety management certification held by 40K+ organisations globally.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the market size for the pet relaxants market?
The global pet relaxants market is anticipated to grow from USD 302.95 Million in 2023 to USD 461.27 Million by 2030, at a CAGR of 6.19% during the forecast period. -
• Which region is domaining in the pet relaxants market?
North America accounted for the largest market in the pet relaxants market. North America accounted for 38% market share of the global market value. -
• Who are the major key players in the pet relaxants market?
Bayer, Pfizer, Zoetis, VetriScience, Solid Gold Pet, LLC, Nootie, Vital Planet, Helopssa, Royce Naturals, FURALAND, Hemp Well, PREMIUM CARE, THUNDERWORKS, Pet Naturals, NaturVet, Feliway, Richard's Organics, Great Pet Media, Beaphar, Oralx -
• What is the latest trend in the pet relaxants market?
The growing need for high-end pet items More and more pet owners are prepared to spend more money on premium pet supplies, such as tranquillizers. This is fueling expansion in the market for high-end pet tranquillizers.
The Pet Relaxants Market is projected to reach $2.31 Bn by 2035, up from $1.13 Bn in 2025 — a 7.40% CAGR equating to roughly 2.0× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.